NeoProgen, Inc. a Baltimore-based company led by Medtech entrepreneur Bill Niland, has chosen Colombia for its first-in-human clinical trial as it develops a cell therapy for patients following a heart attack. bioaccess™ will help NeoProgen select a research center and obtain institutional review board (IRB) approval to initiate its trial. The biotech company is developing a cell therapy that could help patients who have suffered a heart attack.
Read MoreReGelTec, Inc., a Baltimore-based medical device startup company that is developing the next generation of minimally invasive spinal implants for lower back pain and degenerative disc disease, has chosen Colombia and bioaccess™ as its CRO to conduct the first-in-human clinical trial of its Hydrafil System. bioaccess™ will help ReGelTec with its institutional review board (IRB)/ethics committee approval and regulatory approval at Colombia's regulatory agency (INVIMA).
Read More
